Shun-li Zheng1, Qing-sheng Yang, Xiao-hong Ma. 1. Department of Cardiothoracic Surgery, First Affiliated Hospital of Jinan University, Guangzhou 510630, China. zsurely@hotmail.com
Abstract
OBJECTIVE: To investigate the effect of Chinese recipe, Wuye Decoction (WYD), on immune function in patients with non-small cell lung cancer (NSCLC). METHODS:Eighty-two patients of NSCLC with pathologically confirmed diagnosis, who had received operative treatment and completed the post-operational chemotherapy, were randomly assigned into 2 groups. Group A (42 cases) received WYD and Group B (40 cases) received no specific medicine. Positive rate of various peripheral lymphocyte subsets, including CD3, CD4, CD8, CD16, CD19 and CD25, in both groups was observed immediately after chemotherapy (T(0)) and 3 months later (T(1)), the same indexes of 20 healthy volunteers allocated in Group C were also determined at T(0) for control. RESULTS: The positive rates of CD4, CD4/CD8, CD16, CD19 and CD25 were significantly lower (P < 0.05) while that of CD8 was significantly higher (P < 0.05) in Group A and B at T(0) than those in Group C; at T(1), these indexes, except CD25, got significantly restored in Group A with the level approaching normal range (P > 0.05), and showed significant difference from those in Group B (P < 0.05), since these indexes in that group remained unchanged at the corresponding period. As for CD25, it was insignificantly changed in Group A after WYD treatment, and thus, at T(1), it was still lower than that in Group C (P < 0.05) and showed insignificant difference as compared with that in Group B (P > 0.05). Comparison of CD3 among the 3 groups showed no significant difference (P > 0.05). CONCLUSION: WYD could activate the immune function of NSCLC patients, and so it is recommended to be used in the treatment of NSCLC in clinical practice.
RCT Entities:
OBJECTIVE: To investigate the effect of Chinese recipe, Wuye Decoction (WYD), on immune function in patients with non-small cell lung cancer (NSCLC). METHODS: Eighty-two patients of NSCLC with pathologically confirmed diagnosis, who had received operative treatment and completed the post-operational chemotherapy, were randomly assigned into 2 groups. Group A (42 cases) received WYD and Group B (40 cases) received no specific medicine. Positive rate of various peripheral lymphocyte subsets, including CD3, CD4, CD8, CD16, CD19 and CD25, in both groups was observed immediately after chemotherapy (T(0)) and 3 months later (T(1)), the same indexes of 20 healthy volunteers allocated in Group C were also determined at T(0) for control. RESULTS: The positive rates of CD4, CD4/CD8, CD16, CD19 and CD25 were significantly lower (P < 0.05) while that of CD8 was significantly higher (P < 0.05) in Group A and B at T(0) than those in Group C; at T(1), these indexes, except CD25, got significantly restored in Group A with the level approaching normal range (P > 0.05), and showed significant difference from those in Group B (P < 0.05), since these indexes in that group remained unchanged at the corresponding period. As for CD25, it was insignificantly changed in Group A after WYD treatment, and thus, at T(1), it was still lower than that in Group C (P < 0.05) and showed insignificant difference as compared with that in Group B (P > 0.05). Comparison of CD3 among the 3 groups showed no significant difference (P > 0.05). CONCLUSION: WYD could activate the immune function of NSCLCpatients, and so it is recommended to be used in the treatment of NSCLC in clinical practice.
Authors: S Ishigami; S Natsugoe; K Tokuda; A Nakajo; X Che; H Iwashige; K Aridome; S Hokita; T Aikou Journal: Cancer Date: 2000-02-01 Impact factor: 6.860
Authors: Julia S Schleypen; Nicole Baur; Robert Kammerer; Peter J Nelson; Karl Rohrmann; Elisabeth F Gröne; Markus Hohenfellner; Axel Haferkamp; Heike Pohla; Dolores J Schendel; Christine S Falk; Elfriede Noessner Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531